About AM-pharma
AM-Pharma’s purpose is to save the lives of patients confronted with kidney disease, sepsis and organ injury. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary recombinant human alkaline phosphatase has the potential to become the first treatment specifically developed for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.
OUR MISSION
At AM-Pharma, we strive to improve the quality of life for patients with kidney disease, sepsis and organ injury, initially focusing on saving the lives of patients with sepsis-associated acute kidney injury (SA-AKI).
Our investors
LATEST NEWS
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
- Trial to confirm potential of AM-Pharma’s recombinant alkaline…
AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board
Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an…
AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team
Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an…
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI
€23m (US$25.5m) equity provided mainly by US-based Cowen…
AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury
Juliane Bernholz has joined as Chief Operating Officer
…
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
Financing co-led by new investors LSP and Andera Partners, with…
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
JAMA paper to be presented at ESICM conference in Paris
New…
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Study shows use of recAP results in greater than 40% relative…
LATEST NEWS
AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial
- First patients with COVID-19 enrolled in the REVIVAL Phase…
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
- Trial to confirm potential of AM-Pharma’s recombinant alkaline…
AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board
Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an…
AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team
Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an…
AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI
€23m (US$25.5m) equity provided mainly by US-based Cowen…
AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury
Juliane Bernholz has joined as Chief Operating Officer
…
AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury
Financing co-led by new investors LSP and Andera Partners, with…
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
JAMA paper to be presented at ESICM conference in Paris
New…
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Study shows use of recAP results in greater than 40% relative…
